In this review, we aim to provide a comprehensive description of the molecular mechanisms of resistance to CD19-CAR T cell and BsAbs therapy, distinguishing between CAR and antibody-related factors, tumor-intrinsic determinants, host characteristics, and the role of the TME. Here, CD19 is linked to neoplasm.